BIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bio-Rad Laboratories Inc (BIO) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, the financial performance shows significant declines in net income and EPS, and analysts have lowered price targets due to weak guidance. While hedge funds are buying, there are no strong positive catalysts or trading signals to justify immediate investment.
The stock is showing bearish signals with the MACD histogram below zero and negatively expanding, RSI at 27.333 indicating a lack of momentum, and moving averages in a bearish alignment (SMA_200 > SMA_20 > SMA_5). The current price of $261.82 is below the pivot level of $274.216, with key support at $263.043 and resistance at $285.389.
Hedge funds are buying, with a significant increase in buying activity (333305.80% over the last quarter).
No recent news or congress trading data to support positive sentiment.
In Q4 2025, revenue increased by 3.85% YoY to $693.2 million, but net income dropped significantly by 200.59% to $720 million. EPS also fell by 204.22% YoY to 26.65, and gross margin declined by 2.89% to 49.74%.
Analysts have lowered price targets recently. Wells Fargo reduced the target to $320 from $340, citing weak guidance and a Q4 miss. UBS lowered the target to $335 from $350, noting messy margins and unexpected headwinds. Ratings are mixed, with one Buy and one Equal Weight.
